SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending after its latest update and Eagle Line progress, which led to significant investor debate over the company's continued pre-revenue status, ongoing cash burn, and a perceived lack of transparency regarding production yields and specific OEM partners, despite some community members remaining bullish on its long-term solid-state battery technology and licensing strategy.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending as a short-seller retracted its prior allegations of financial crimes, sparking a rebound and bullish sentiment ahead of upcoming earnings. The community is actively debating if this removes a major overhang, setting the stage for strong analyst upgrades and a short squeeze, or if broader software sector fears will still impact the stock.

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

NovoCure Ltd

NovoCure is trending following a recent FDA approval of its Optune Pax therapy for locally advanced pancreatic cancer, based on positive PANOVA-3 trial results demonstrating a statistically significant survival benefit. The community is actively debating the clinical significance of this survival extension for patients, while also considering the broader potential of its Tumor Treating Fields platform across various oncology indications amid past commercial challenges.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending amid a severe sector-wide sell-off, with widespread fears that advanced AI tools will disrupt or replace traditional enterprise software. However, many in the community and market analysts view this as an irrational overreaction, highlighting Salesforce's strong fundamentals, AI integration, and current undervaluation as a significant buying opportunity.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following news of a proposed $1 billion convertible note offering, which has sparked intense debate among investors. Bulls view the capital raise as a strategic move to accelerate growth and pursue new opportunities, while bears express concern over potential dilution and the company's long-term funding strategy.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as the community eagerly discusses its oral obesity drug, VK2735, advancing directly to Phase 3 trials, accelerating its pipeline and strengthening its competitive position in the lucrative GLP-1 market.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is seeing significant discussion following its robust Q4 2025 earnings, which revealed record revenue, gross margin, and its first profitable fiscal year, with the CEO highlighting AI as an increasing tailwind for its edge platform. Long-term investors are celebrating this financial inflection point as a potential turnaround, though some in the community remain wary of the rally's sustainability.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco Systems is trending after its Q1 FY26 earnings initially saw shares dip due to a lower-than-anticipated gross margin forecast linked to rising memory-chip costs, despite beating revenue and EPS expectations. However, the stock quickly reversed as the company emphasized surging AI infrastructure demand and raised its full-year guidance, sparking community debate over its "AI plumbing powerhouse" role and its stock price nearing dot-com era highs.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for NEREUS to prevent motion-induced vomiting, which the community believes holds blockbuster potential for GLP-1 induced nausea. Investors are also keenly anticipating the upcoming Bysanti approval and actively discussing a potential buyout due to the company's de-risked assets and promising pipeline.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. It also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment offers products and services sold for applications within the data center, communication networks, and commercial and industrial markets in North America and Latin America. The Asia Pacific segment includes products and services sold for applications within the data center, communication networks, and commercial or industrial markets throughout Greater China, Australia and New Zealand, Southeast Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Columbus, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertiv Holdings is trending sharply higher following its robust fourth-quarter earnings and optimistic 2026 guidance, fueled by exceptional demand for AI infrastructure, especially liquid cooling and power management systems from hyperscale data centers, resulting in a record backlog. The community is largely bullish on its role as a critical AI infrastructure provider, anticipating continued growth despite some debate over its current valuation and evolving cooling technologies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The strategic review could include partnerships, joint ventures, mergers, acquisitions, licensing deals, or other transactions, according to Quince Therapeutics.</li><li>On January 29, QNCX shares plunged 91.5% after the company said it would halt clinical development of its lead asset Edsp.</li><li>Lucid Capital double-downgraded Quince Therapeutics to ‘Sell’ from ‘Buy’ late last month.</li></ul>Shares of Quince Therapeutics, Inc. (QNCX) surged nearly 60% in pre-market trading on Tuesday after the company announced that it has appointed LifeSci Capital as its exclusive financial advisor to support a restructuring effort and review strategic alternatives.The strategic review could include partnerships, joint ventures, mergers, acquisitions, licensing deals, or other transactions, according to the company. In addition to assessing these opportunities, LifeSci Capital will advise Quince Therapeutics on any potential restructuring of its liabilities.Quince, a late-stage biotechnology firm focusing on rare disease treatments, added that it will not provide updates during the review and will disclose developments only if its board approves a specific action or deems further communication necessary.<h2 class="st-heading-2">96% Market Value Erased In Just Over A Week</h2>Quince Therapeutics’ stock has been under heavy selling pressure lately. On January 29, QNCX shares plunged 91.5% after the company <a href="https://stocktwits.com/news-articles/markets/equity/qncx-stock-plummets-over-90-percent/cmyipqPR410">said</a> it would halt clinical development of its lead asset, dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP).The late-stage trial in 105 patients with Ataxia-Telangiectasia, a rare and inherited neurodegenerative disorder, did not meet statistical significance for its primary endpoint. The study also missed its key secondary goal. The stock declined a further 37% in the following session.<a href="https://stocktwits.com/symbol/QNCX">QNCX shares</a> have declined nearly 96% from January 28 to Monday’s close.<h2 class="st-heading-2">Wall Street Turns Bearish</h2>The results prompted Lucid Capital to double downgrade Quince Therapeutics to ‘Sell’ from ‘Buy’ with a price target of $0, down from $8. The firm noted that the program, which is Quince’s asset, will be discontinued, and, given that the company’s estimated cash and long-term debt are nearly equal, it sees no value in the shares.The company has also faced mounting financial pressure. In the third quarter of fiscal 2025, Quince reported a net loss of $13.3 million, more than quadrupling the $3.2 million loss from a year earlier. Total operating expenses jumped 130% to $13.4 million.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/QNCX_jpg_46df9654d8.webp" alt="QNCX.jpg" width="927" height="111"><figcaption>QNCX's Sentiment Meter and Message Volumes at Premarket on Feb. 10, 2026 | Source: Stocktwits</figcaption></figure>One bullish user noted the high volumes in after-market trading.<stembedurl>https://stocktwits.com/Risley/message/644527590</stembedurl>However, one bearish user highlighted the company’s shortcomings in the clinical trial.<stembedurl>https://stocktwits.com/Marceltrade/message/644532523</stembedurl>Over the past year, the stock has slumped 91%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/nasdaq-sp500-futures-subdued-tsla-rblx-tsm-hood-kd-stocks-to-watch/cZbUbhPR4Y9">Nasdaq, S&amp;P 500 Futures Subdued After Dow Closes Above 50,000: Why TSLA, RBLX, TSM, HOOD, KD Are On Traders' Radar Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Is QNCX Stock Up 60% Pre-Market After A Near-Total Wipeout?

The company announced that it has appointed LifeSci Capital as its exclusive financial advisor to support a restructuring effort and review strategic alternatives.

This Nano-Cap Biotech Stock Soars 60% Pre-Market Just Days After A Near-Total Wipeout – Here’s What’s Driving The Move

Equity

<ul class="summary-bullets"><li>The National Defense Authorization Act for fiscal 2026 calls on the DoD to integrate FDA-approved breakthrough vascular repair technologies to fix severe artery injuries in arms and legs.</li><li>This would provide an off-the-shelf biologically active vascular conduit when autologous vein harvesting is not feasible, the NDAA states.</li><li>Humacyte says Symvess has been used on the battlefield in Ukraine, with none of the sixteen recipients showing any adverse events such as amputations or infections so far.</li></ul>Humacyte Inc. (HUMA) on Monday announced that the recently adopted FY2026 U.S. Department of Defense (DOD) Appropriations Act includes funding for the procurement of bioengineered blood vessels.The company stated that the DOD funding is intended to support the evaluation and incorporation of biologic vascular repair technologies for warfighters with traumatic vascular injuries.Humacyte stated that its product, Symvess, is the only human-derived bioengineered blood vessel approved by the U.S. Food and Drug Administration (FDA).<a href="https://stocktwits.com/symbol/HUMA">Humacyte shares</a> were up more than 30% in Monday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory at the time of writing.<h2 class="st-heading-2">What Does The NDAA Say?</h2>The National Defense Authorization Act (NDAA) for fiscal 2026 calls on the DoD to integrate FDA-approved breakthrough vascular repair technologies&nbsp;to fix severe artery injuries in arms and legs.This would provide an off-the-shelf biologically active vascular conduit when autologous vein harvesting is not feasible, the NDAA states.Autologous vein harvesting refers to the surgical removal of the patient’s own healthy vein, which is usually the great saphenous vein (GSV) in the leg. This is used as a graft, typically in coronary artery bypass grafting (CABG) or peripheral vascular surgery.“This historic, first-of-its-kind federal investment will help ensure our soldiers continue to have access to cutting-edge treatments and state-of-the-art care whenever and wherever they need it,” said Humacyte founder and CEO, Laura Niklason.<h2 class="st-heading-2">What Is Humacyte’s Symvess?</h2>Symvess is a human-derived biologic vessel&nbsp;used when urgent revascularization is needed to avoid imminent limb loss and an autologous vein graft is not feasible.The company says Symvess is off-the-shelf and ready to use, with no immune response observed to date. It also states that Symvess has low susceptibility to infection.Humacyte says Symvess has been used on the battlefield in Ukraine, with none of the sixteen recipients showing any adverse events such as amputations or infections so far.<a href="https://stocktwits.com/symbol/HUMA">HUMA stock</a> is up 26% year-to-date, but down 71% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/momentus-nasa-partnership-space-operations-mnts-stock/cZbvGE4R4o3">Momentus Partners With NASA For In-Orbit Servicing, Space Operations — MNTS Stock Rises Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

HUMA Stock Is Soaring Today – Here’s Everything To Know About The DOD Funding Fueling The Surge

The company stated that its product, Symvess, is the only human-derived bioengineered blood vessel approved by the U.S. Food and Drug Administration.

<ul class="summary-bullets"><li>The agreement resolves ongoing legal issues between the companies.</li><li>Maxeon will terminate all pending and potential patent enforcement actions against Aiko.</li><li>Maxeon's infringement case against Aiko featured a patent covering proprietary and core solar cell designs for rear or back contact technologies.&nbsp;</li></ul>Shares of Maxeon Solar Technologies (MAXN) popped over 19% in pre-market trading on Friday after the company signed a patent licensing agreement with Shanghai Aiko Solar Energy for Maxeon’s Back Contact solar cell and module technology.Under the deal, Aiko will gain rights to use all of Maxeon’s Back Contact patents outside the United States, including existing intellectual property and any new patents added over the next five years.The agreement also resolves ongoing legal issues between the companies. Maxeon will terminate all pending and potential patent enforcement actions against Aiko, while Aiko will end its efforts to invalidate Maxeon’s patents.<h2 class="st-heading-2">Maxeon's Lawsuits Against Aiko</h2>Maxeon Solar had initially filed a lawsuit before the Mannheim Regional Court concerning infringement of its patent in 2023. The patent covered proprietary and core solar cell designs for rear or back contact technologies, commonly known as All-Back Contact (ABC) or Interdigitated Back Contact (IBC) solar cells.&nbsp;In June 2024, Maxeon opened a second lawsuit against Aiko and several of its partners before the Unified Patent Court Local Division in Düsseldorf, claiming infringement of its patent EP3065184.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/MAXN">MAXN</a> turned 'extremely bullish' from 'bullish' a day earlier, amid 'extremely high' message volumes.One user highlighted patent and infringement details.<stembedurl>https://stocktwits.com/Figs999/message/644253077</stembedurl>Another user spoke about the company's operations in the U.S.<stembedurl>https://stocktwits.com/MMACRON/message/644262887</stembedurl>The stock has gained around 30% so far in 2026.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did MAXN Stock Surge 19% In Pre-Market Today?

The company signed an agreement with Shanghai Aiko Solar Energy under which Aiko will gain rights to use all of its Back Contact patents outside the U.S., including existing intellectual property and any new patents added over the next five years.

<ul class="summary-bullets"><li>Palladyne expects to complete the deliverables by the third quarter of 2026.</li><li>The contract projected to generate nearly $1 million in revenue for fiscal 2026.</li><li>The win positions Palladyne for a bigger involvement in future long-duration missile programs, the company said.&nbsp;</li></ul>Shares of Palladyne AI Corp. (PDYN) jumped more than 10% in pre-market trading on Tuesday after the company signed an agreement with a major U.S. defense prime contractor to supply a mission-critical subsystem supporting missile propulsion for an existing U.S. missile program.<a href="https://stocktwits.com/symbol/PDYN">PDYN shares</a> jumped 17% after the opening bell.Palladyne expects to complete the deliverables by the third quarter of 2026, with the contract projected to generate nearly $1 million in revenue for the year. The win also positions Palladyne for a bigger involvement in future long-duration missile programs, the company said.“Beyond the initial contract, we believe we are well positioned for growing annual revenues from this program,” said Ben Wolff, CEO of Palladyne AI.<h2 class="st-heading-2">Palladyne’s Latest Contracts</h2>This comes on the back of two recent contracts. Last month, Palladyne AI was awarded a contract by the Air Force Research Laboratory (AFRL) for project HANGTIME to enable autonomous systems to operate as a coordinated unit. The project will use Palladyne’s SwarmOS to connect drones, ships, satellites, and ground systems, allowing them to share intelligence, adapt in real time, and execute synchronized missions across domains.In a separate development, Palladyne’s subsidiary GuideTech secured a contract with Portal Space Systems to support next-generation maneuverable spacecraft. GuideTech will provide navigation, guidance, spacecraft modeling, embedded software, and avionics expertise, expanding Palladyne’s footprint into the space sector.Palladyne also released its FY2026 forecast, expecting revenue between $24 million and $27 million, representing significant growth driven by new contracts, rising customer demand, and the integration of recently acquired businesses.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained in the ‘extremely bullish’ territory over the past 24 hours, accompanied by ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/PDYN_jpg_f922841080.webp" alt="PDYN.jpg">One user expects the stock to climb to $10. It is currently at $7.91.<stembedurl>https://stocktwits.com/Lando4/message/643785073</stembedurl>The stock has seen heavy buying interest so far in 2026, surging 84%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Palladyne AI Corp. logo is seen displayed on a smartphone screen. 

Why Did PDYN Stock Pop Over 10% In Pre-Market Today?

The company signed an agreement with a major U.S. defense prime contractor to supply a subsystem that supports missile propulsion.

Palladyne AI Stock Is Surging After Landing A Pentagon-Linked Missile Contract 

<ul class="summary-bullets"><li>Massimo stated that it plans to integrate its manufacturing scale and brand awareness with FST’s full-stack AI capabilities, including intelligent control platforms, health-technology modules, and proprietary AI middleware.</li><li>Its purchase consideration for 100% of FST’s equity ranges between $27 million and $35 million.</li><li>In December, the company announced plans to introduce the Sentinel 1500, a utility terrain vehicle featuring a fully enclosed factory cab with integrated heating and air conditioning, in the first quarter of 2026.</li></ul>Massimo Group (MAMO) shares declined more than 64% in Tuesday’s pre-market session after the company announced that it has signed a Letter of Intent (LOI) to acquire FST Development.Massimo stated that, as per the non-binding LOI, it will acquire 100% of the equity interests of FST, a company that specializes in intelligent hardware and AI-driven system-level solutions.<h2 class="st-heading-2">Why Does Massimo Want To Acquire FST?</h2>Explaining the rationale behind its intent to acquire FST, Massimo stated that it plans to integrate its manufacturing scale and brand awareness with FST’s full-stack AI capabilities, including intelligent control platforms, health-technology modules, and proprietary AI middleware.“The proposed transaction represents a major strategic milestone for Massimo, positioning the Company at the convergence of two rapidly expanding global trends: AI-enabled outdoor mobility and next-generation digital health robotics,” Massimo stated in its announcement.Massimo stated that the pre-money equity valuation of FST is between $38 million and $50 million. However, its purchase consideration for 100% of FST’s equity ranges between $27 million and $35 million.The company added that it may satisfy the purchase consideration either by issuing its common stock, or through cash, or via a combination of both.<h2 class="st-heading-2">What Does Massimo Do?</h2>Massimo is a Garland, Texas-based company that manufactures and distributes powersports vehicles, utility terrain vehicles (UTVs), electric mobility solutions, and related accessories.In December, the company announced plans to introduce the Sentinel 1500, a UTV featuring a fully enclosed factory cab with integrated heating and air conditioning, in the first quarter of 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/MAMO">Massimo</a> trended in the ‘extremely bullish’ territory while message volumes were at ‘high’ levels.One user stated that the company’s terms set out in the LOI are “manageable if an agreement is reached in March.”<stembedurl>https://stocktwits.com/Aburose/message/643771817</stembedurl><a href="https://stocktwits.com/symbol/MAMO">MAMO stock</a> is down 21% year-to-date, but up 3% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pltr-stock-upgrade-after-blowout-q4-palantir-clearest-ai-winner/cZbiqZLR4lF">PLTR Stock Surges On An Upgrade Following Blowout Q4, Analyst Calls It 'One Of The Clearest AI Winners'</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trading digital board showing the data on global stock market crash. | Image source: Getty Images

Why Is MAMO Stock Falling Pre-Market Today?

Massimo stated that, as per the non-binding LOI, it will acquire 100% of the equity interests of FST, a company that specializes in intelligent hardware and AI-driven system-level solutions.

<ul class="summary-bullets"><li>The FDA’s concerns were limited to packaging, labeling, and administration issues, the company said.</li><li>Aquestive has already modified the pouch design, updated instructions for use, and revised labelling.</li><li>The firm is also targeting global expansion plans for Anaphylm after initiating regulatory discussions in Canada, Europe, and the U.K last year.</li></ul>Shares of Aquestive Therapeutics (AQST) surged more than 35% on Monday morning, after receiving a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) seeking approval of Anaphylm, a sublingual film to treat severe Type I allergic reactions.A CRL indicates that while a drug has not been approved in its current form, it allows the sponsor to address the issues raised by the FDA and seek re-approval.<h2 class="st-heading-2">FDA’s Concerns</h2>The FDA’s concerns were limited to packaging, labeling, and administration issues identified in a human factors validation study. The FDA noted that some users had difficulty opening the pouch and correctly placing the film, which could pose safety risks during emergency situations. The agency did not raise questions about the drug’s comparability data or manufacturing processes, the company said.To address the feedback, Aquestive has modified the pouch design, updated instructions for use, and revised labeling. The company plans to conduct a new human factors study alongside a single pharmacokinetics (PK) study requested by the FDA. No additional trials are required.Based on the initial review, Aquestive expects to resubmit the application as early as the third quarter of 2026 and will seek a rapid review.<h2 class="st-heading-2">Europe Update</h2>Aquestive is also targeting global expansion plans for Anaphylm after initiating regulatory discussions in Canada, Europe, and the U.K. in 2025. The European Medicines Agency indicated that no additional clinical trials are required, with submissions in Europe and Canada expected in the second half of 2026. The company also anticipates feedback from the U.K.’s MHRA in the first quarter of 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘bullish’ from ‘neutral’ a session earlier, amid ‘high’ message volumes.&nbsp;<img src="https://news.stocktwits-cdn.com/AQST_jpg_c092cd62f6.webp" alt="AQST.jpg">One user brushed off concerns about the CRL, noting there were no key issues.<stembedurl>https://stocktwits.com/BigGainTom/message/643649716</stembedurl>While the stock has gained nearly 35% over the past year, its year-to-date losses are around 40%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/precious-metals-extend-historic-rout/cZbg8EJR4kf">Gold, Silver Continue To Decline – Analysts Warn Of Crowded Trades As Precious Metals Extend ‘Historic Rout’</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did AQST Stock Jump 35% Today?

The company received a Complete Response Letter from the U.S. Food and Drug Administration for its New Drug Application seeking approval of Anaphylm, a sublingual film to treat severe Type I allergic reactions.

<ul class="summary-bullets"><li>Quince on Thursday announced that the primary endpoint in the late-stage trial evaluating the asset in 105 patients with Ataxia-Telangiectasia did not reach statistical significance.</li><li>The study further did not meet its key secondary endpoint though the therapy was generally well tolerated with no clinically meaningful safety concerns, the company said. &nbsp;</li></ul> Shares of Quince Therapeutics, Inc. (QNCX) closed 92% lower on Thursday after the company said that it has decided to cease clinical development of its lead asset, dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP).Quince <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20260129349326/en/Quince-Therapeutics-Announces-Topline-Results-from-Pivotal-Phase-3-NEAT-Clinical-Trial-of-eDSP-in-Ataxia-Telangiectasia">announced</a> that the primary endpoint in the late-stage trial evaluating the asset in 105 patients with Ataxia-Telangiectasia did not reach statistical significance.Moreover, the study did not meet its key secondary endpoint though the therapy was generally well tolerated with no clinically meaningful safety concerns, the company said. &nbsp;<h2 class="st-heading-2">What Is Ataxia-Telangiectasia?</h2>Ataxia-Telangiectasia (A-T) is a rare, inherited neurodegenerative disorder caused by mutations in the ATM gene, leading to progressive loss of coordination, small, visible blood vessels in the eyes/skin, a weakened immune system, and a high risk of cancer, typically appearing in early childhood with unsteady walking and balance issues.Patients with the condition have a median lifespan of approximately 25 to 30 years. There are no approved therapies for the disorder in any global market, as per Quince, though there are about 4,600 diagnosed patients with A-T in the U.S.Shares of the company edged up 2% after hours at the time of writing.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around QNCX shares rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A Stocktwits user said that they are adding more shares in the company for the “epic return to glory.”<stembedurl>https://www.stocktwits.com/McGinvests/message/643354295</stembedurl>Another user termed the selloff as “brutal” and hinted at a possible bankruptcy filing.<stembedurl>https://www.stocktwits.com/SierraIndiaDavid/message/643354859</stembedurl><a href="https://stocktwits.com/symbol/QNCX">QNCX stock</a> has lost 84% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/krro-shares-jump-on-analyst-upgrades/cmyimzWR41O">KRRO Shares Jump 13% On Analyst Upgrades — What’s Driving The Optimism?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Shares of InMode have fallen nearly 12% over the past 12 months. 

Why Did QNCX Stock Plummet Over 90% Today?

The company announced that it has decided to cease clinical development of its lead asset dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP). 

<ul class="summary-bullets"><li>The clearance allows the clinical-stage biotech firm to move ahead with preparations for a planned Phase 1b registrational study.</li><li>Serina&nbsp;had previously received written feedback from the agency supporting its proposed registrational trial design under an NDA pathway.</li><li>The latest update follows a setback in November 2025, when the FDA placed a clinical hold on the application to initiate clinical trials.</li></ul>Shares of Serina Therapeutics (SER) surged more than 70% in pre-market trading on Thursday after the company announced that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for SER-252, a therapy to treat patients with Parkinson’s disease.SER-252 is an experimental apomorphine-based therapy to provide continuous dopaminergic stimulation, an approach shown to ease levodopa-related motor complications such as dyskinesia in people with Parkinson’s disease.<a href="https://stocktwits.com/symbol/SER">SER stock</a> had surged nearly 35% in after-hours trading on Wednesday.<h2 class="st-heading-2">SER-252: What Next?</h2>The clearance allows the clinical-stage biotech firm to move ahead with preparations for a planned Phase 1b registrational study in patients with advanced Parkinson’s disease. The IND clearance follows extensive regulatory engagement between Serina and the FDA.The company previously received written feedback from the agency supporting its proposed registrational trial design under an NDA pathway.“With FDA alignment on a registrational development strategy under a 505(b)(2) NDA pathway, we believe SER-252 has a clear and efficient path forward toward addressing a significant unmet medical need,” said Steve Ledger, Chief Executive Officer of Serina Therapeutics.The latest update follows a setback in November 2025, when the FDA placed a clinical hold on Serina’s application to initiate clinical trials. That hold was tied to a request for additional information related to an excipient in the drug’s formulation, a non-active substance included in a drug formulation alongside the active ingredient. Serina emphasized that the FDA’s concerns did not involve SER-252’s active drug substance or its proposed mechanism of action.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bearish’ a day earlier, accompanied by ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/SER_jpg_f485987591.webp" alt="SER.jpg" width="927" height="114"><figcaption>SER's Sentiment Meter and Message Volumes in Premarket on Jan. 29, 2026 | Source: Stocktwits</figcaption></figure>One bullish user said the stock price could double with good volumes.<stembedurl>https://stocktwits.com/Targeted_Trading/message/643250368</stembedurl>Another user simply said “massive news”, and the stock could climb to $8. It is currently around $4.<stembedurl>https://stocktwits.com/madape/message/643249925</stembedurl>SER shares have shed more than 40% in the past year, though its year-to-date gains are over 25%.Read also: <a href="http://stocktwits.com/news-articles/markets/equity/nasdaq-sp500-futures-higher-meta-tsla-ser-mp-crml-stocks-to-watch/cmyidGCR4KJ">Nasdaq, S&amp;P 500 Futures Climb Ahead Of Apple Earnings: Why META, TSLA, MP, CRML, SER Are On Traders' Radar Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Why Did SER Stock Surge Over 70% In Pre-Market Today?

The U.S. Food and Drug Administration cleared its Investigational New Drug application for SER-252, a therapy to treat patients with Parkinson’s disease.

SER Stock Surges Over 70% Pre-Market After FDA Clears Path For Parkinson’s Therapy

<ul class="summary-bullets"><li>The contract is issued under the VA Federal Supply Schedule and includes pre-negotiated pricing.</li><li>The agreement provides more than nine million enrolled veterans access to&nbsp;esophageal&nbsp;precancer testing.</li><li>Trading in PAVM shares was halted at 09:58 ET.</li></ul>Shares of PAVmed Inc. (PAVM) jumped more than 250% on Wednesday morning after its subsidiary, Lucid Diagnostics Inc. (LUCD), won a contract from the U.S. Department of Veterans Affairs (VA) to supply its EsoGuard Esophageal DNA Test for detecting esophageal precancer across the VA healthcare system.The agreement provides more than nine million enrolled veterans access to&nbsp;esophageal&nbsp;precancer testing.<a href="https://stocktwits.com/symbol/PAVM">PAVM</a> was among the top trending tickers on Stocktwits at the time of writing. <a href="https://stocktwits.com/symbol/LUCD">LUCD</a> shares jumped 23% to their highest levels since May 2025.<h2 class="st-heading-2">Contract Details</h2>The contract is issued under the VA Federal Supply Schedule and includes pre-negotiated pricing that aligns with the Medicare reimbursement rate set by the Centers for Medicare &amp; Medicaid Services. This structure allows VA hospitals and clinics nationwide to procure EsoGuard through a single, standardized framework.“The VA operates at significant clinical and operational scale, and selection by a healthcare system of this size reflects the strength of the clinical evidence supporting EsoGuard,” said Shaun O'Neil, President and Chief Operating Officer of Lucid Diagnostics.&nbsp;&nbsp;Lucid Diagnostics focuses on early cancer prevention diagnostics, particularly for patients with gastroesophageal reflux disease who face an elevated risk of developing esophageal precancer and cancer.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for PAVM on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, accompanied by ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/PAVMED_jpg_a10dfa8673.webp" alt="PAVMED.jpg" width="925" height="96"><figcaption>PAVM's Sentiment Meter and Message Volumes at 10:20 a.m. ET on Jan. 21, 2026 | Source: Stocktwits</figcaption></figure>Sentiment for LUCD changed to ‘bullish’ from ‘neutral’ a day earlier, while message volumes were ‘extremely high’.One user believes the news has ‘real value’.<stembedurl>https://stocktwits.com/pow7904/message/642397455</stembedurl>PAVmed implemented a 1-for-30 reverse stock split on January 2.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/gold-rises-to-record-highs-as-investors-seek-out-safe-haven-assets/cmUDMEjR4fK">Gold Jumps To All-Time Highs – Veteran trader Peter Brandt Says $8,000 An Ounce Is On The Cards</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

PAVM Stock Shot Up Over 250% Today – What’s The Deal With The Department of Veterans Affairs?

PAVM Stock - The company’s subsidiary, Lucid Diagnostics, secured a contract from the U.S. Department of Veterans Affairs to provide its EsoGuard Esophageal DNA Test for the detection of esophageal precancer.

The company’s subsidiary, Lucid Diagnostics, secured a contract from the U.S. Department of Veterans Affairs to provide its EsoGuard Esophageal DNA Test for the detection of esophageal precancer.

<ul class="summary-bullets"><li>The company posted a net income available to common shareholders of $89.1 million, compared to a net loss of $286.4 million in the third quarter 2024.</li><li>Its revenue also jumped to $277.9 million, compared to $175.4 million in the third quarter 2024.</li><li>The company said strong financial performance in the third quarter was led by the Capital Markets segment.&nbsp;</li></ul>BRC Group Holdings, formerly known as B.Riley Financial, rallied in after-market hours on Wednesday after it announced its delayed quarterly results.&nbsp;The company filed financial reports for three quarters within 120 days, achieving NASDAQ compliance ahead of the deadline, it said in a regulatory filing.&nbsp;<h2 class="st-heading-2">Q3 Results</h2>The company posted a net income available to common shareholders of $89.1 million, compared to a net loss of $286.4 million in the third quarter 2024. The company said basic and diluted earnings per common share were $2.91 compared to a loss per share of $9.39 in the third quarter 2024.Its revenue also jumped to $277.9 million, compared to $175.4 million in the third quarter 2024. The company said strong financial performance in the third quarter was led by the Capital Markets segment with $65.4 million in services and fee revenues, the highest quarterly total since the fourth quarter of 2023.“We are pleased with the third quarter financial results. B. Riley Securities had a very strong quarter across investment banking, advisory, and research and trading with equity and debt capital raises totaling approximately $10.5 billion while delivering product innovation,” Bryant Riley, Chairman and Co-Chief Executive Officer of BRC, said.&nbsp;“Our Communications segment produced strong cash flow, consistent with previous quarters. B. Riley Wealth enhanced products and services for clients, while reducing costs and integrating its back office,” he added.&nbsp;<h2 class="st-heading-2">B.Riley Woes</h2>BRC’s struggles to file timely earnings reports started after a turbulent period in 2024 when it grappled with soured investments, flaws in financial reporting and a U.S. civil investigation.Franchise Group was a key investor of BRC and its bankruptcy in late 2024 left B. Riley burdened with write-offs of hundreds of millions of dollars and it was unable to file its annual and quarterly reports with US regulators on a timely basis. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around RILY trended in ‘extremely bullish’ territory amid ‘high’ message volume.&nbsp;One user predicted the stock could hit $15 on Thursday.<a href="https://stocktwits.com/SelectiveTrader/message/641848445">https://stocktwits.com/SelectiveTrader/message/641848445</a>Shares of RILY have jumped 53% over the past year.&nbsp; &nbsp;

Chairman, B. Riley & Co. Bryant Riley (L) and CEO, B. Riley & Co. Tom Kelleher. (Photo by Matt Winkelmeyer/Getty Images)

B.Riley Stock Soars Nearly 40% - What’s Behind The Move?

Company said it has filed its delayed quarterly reports and achieved NASDAQ compliance ahead of the deadline. 

BlackRock Institutional Trust Company N.A. - iShares Micro-Cap ETF

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $COIN earnings on Thursday?

IWC
iShares Micro-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWC News

IWCiShares Micro-Cap ETF